Intuitive Surgical · ISRG

[1] Intuitive 2026年第二季度财报

发布日期：2026-07-16

证据文件：/mnt/q/private/stock_site/data/batches/20260908/010_IntuitiveSurgical/01_source.txt

Second quarter 2026 revenue was $2.89 billion, an increase of 19% compared with $2.44 billion in the second quarter of 2025. The higher second quarter revenue was driven by growth in procedure volume, higher da Vinci system leasing revenue, and an increase in the installed base of da Vinci and Ion systems.

[2] Intuitive 2025 Q4财报

发布日期：2026-01-22

证据文件：/mnt/q/private/stock_site/data/batches/20260908/010_IntuitiveSurgical/02_source.txt

| Total revenue | | 2,866.2 | | | | 2,505.1 | | | | 2,413.5 | |

[3] Intuitive 2025Q3财报

发布日期：2025-10-21

证据文件：/mnt/q/private/stock_site/data/batches/20260908/010_IntuitiveSurgical/04_source.txt

Third quarter 2025 revenue was $2.51 billion, an increase of 23% compared with $2.04 billion in the third quarter of 2024. The higher third quarter revenue was driven by growth in procedure volume, higher da Vinci system placements, and an increase in the installed base of systems.

[4] Intuitive 2026Q1财报

发布日期：2026-04-21

证据文件：/mnt/q/private/stock_site/data/batches/20260908/010_IntuitiveSurgical/05_source.txt

- First quarter 2026 revenue of $2.77 billion increased 23%, compared with $2.25 billion in the first quarter of 2025.

[5] Intuitive FY2025 10-K（Stocklight副本）

发布日期：2026-02-03

证据文件：/mnt/q/private/stock_site/data/batches/20260908/010_IntuitiveSurgical/06_source.txt

Total revenue $ 10,064.7 $ 8,352.1 $ 7,124.1

[7] Intuitive 2026Q2完整SEC 10-Q

发布日期：2026-07-21

证据文件：/mnt/q/private/stock_site/data/batches/20260909/evidence/010_IntuitiveSurgical/q2_10q_secfull.txt

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Six Months Ended June 30, in millions 2026 2025 Operating activities: Net income $ 1,649.2 $ 1,367.9 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and loss on disposal of property, plant, and equipment 371.2 289.6 Amortization of intangible and other assets 59.9 24.4 Accretion of discounts, amortization of premiums, and (gains) losses on investments, net ( 19.0 ) ( 27.4 ) Gain on sale of business and assets ( 7.9 ) — Deferred income taxes 370.3 ( 29.4 ) Share-based compensation expense 419.4 381.4 Changes in operating assets and liabilities, net of effects of acquisitions: Accounts receivable ( 49.8 ) ( 44.1 ) Inventory ( 514.6 ) ( 494.2 ) Prepaids and other assets ( 179.0 ) ( 141.8 ) Accounts payable 21.4 72.4 Accrued compensation and employee benefits ( 229.7 ) ( 114.9 ) Deferred revenue 44.7 48.8 Other liabilities 36.8 ( 35.7 ) Net cash provided by operating activities 1,972.9 1,297.0 Investing activities: Purchase of investments ( 1,349.1 ) ( 691.8 ) Proceeds from sales of investments 0.1 249.1 Proceeds from maturities of investments 1,106.0 1,190.0 Proceeds from sale of assets 46.0 — Purchase of property, plant, and equipment ( 215.9 ) ( 271.9 ) Acquisition of business, net of cash, and intellectual property and other investing activities ( 528.2 ) ( 1.2 ) Net cash provided by (used in) investing activities ( 941.1 ) 474.2 Financing activities: Proceeds from issuance of common stock relating to employee stock plans 187.4 183.7 Taxes paid related to net share settlement of equity awards ( 365.4 ) ( 386.3 ) Repurchase of common stock ( 1,443.5 ) ( 181.0 ) Other financing activities ( 20.1 ) — Net cash used in financing activities ( 1,641.6 ) ( 383.6 ) Effect of exchange rate changes on cash, cash equivalents, and restricted cash 8.1 ( 3.5 ) Net increase (decrease) in cash, cash equivalents, and restricted cash ( 601.7 ) 1,384.1 Cash, cash equivalents, and restricted cash, beginning of period 3,407.4 2,062.4 Cash, cash equivalents, and restricted cash, end of period $ 2,805.7 $ 3,446.5 Supplemental and non-cash disclosures: Equipment transfers, including operating lease assets, from inventory to property, plant, and equipment $ 419.3 $ 357.2 Acquisition of property, plant, and equipment in accounts payable and accrued liabilities 68.8 74.8 Unsettled common stock repurchases in accrued liabilities 63.5 —

[8] Intuitive欧洲da Vinci 5创新及Force Feedback CE标志公告

发布日期：2026-09-08

证据文件：/mnt/q/private/stock_site/data/batches/20260909/evidence/010_IntuitiveSurgical/europe_20260908.txt

READING, UK, 8 September 2026 : Intuitive, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced the CE mark approval of Force Feedback instruments for its da Vinci 5 surgical system, as well as a series of new system enhancements to be rolled out across Europe. Force Feedback technology is designed to enhance intra-operative awareness of the force exerted on tissue during surgery, by enabling surgeons to feel push and pull forces through their da Vinci 5 console hand controls and measure these forces through a real time force indicator. Alongside Force Feedback instruments, Intuitive is introducing more than 100 updates and user experience enhancements for da Vinci 5 users in Europe. Powered by da Vinci 5's advanced computing architecture, which provides 10,000 times greater computing power than da Vinci Xi, these advancements represent the continued evolution of Intuitive's most advanced surgical system. "With the introduction of Force Feedback instruments and new capabilities for da Vinci 5 in Europe, we continue to deliver on our vision of a future-ready platform that can evolve with the needs of surgeons, patients and health systems," said Dirk Barten, Intuitive commercial president for Europe. "Across healthcare systems, our customers are challenged to deliver better patient outcomes, while also lowering the total cost of care, expanding access to care for more patients, and improving patient and care team experience. Through our portfolio of da Vinci systems and integrated Intuitive Ecosystem, shaped by over thirty years of expertise, we're continuing to help them meet those challenges."

[9] Intuitive公司新闻稿：良性病症荟萃分析（Finviz/GlobeNewswire转载）

发布日期：2026-09-08 16:05 ET

证据文件：/mnt/q/private/stock_site/data/batches/20260909/evidence/010_IntuitiveSurgical/refresh_10.txt

The study analyzed data from more than 14 million da Vinci, laparoscopic and open procedures across 13 common benign (non-cancerous) conditions, making it the largest comparative meta-analysis of its kind. The authors found da Vinci surgery was associated with statistically significant improvements in select perioperative outcomes compared with laparoscopic and open surgery.

[10] Intuitive投资者活动页

发布日期：2026-09-09抓取；页面无单独发布日期

证据文件：/mnt/q/private/stock_site/data/batches/20260909/evidence/010_IntuitiveSurgical/refresh_01.txt

Upcoming Events 07/16/26 - 1:30 PM PDT Q2 2026 INTUITIVE Earnings Conference Call [Listen to Webcast](https://edge.media-server.com/mmc/p/dekvotz4/)

[11] Intuitive 7月23日公司章程修订8-K

发布日期：2026-07-27

证据文件：/mnt/q/private/stock_site/data/batches/20260909/evidence/010_IntuitiveSurgical/jul_8k.txt

On July 23, 2026, the Board of Directors of Intuitive Surgical, Inc. (the “Company”) amended and restated the Company’s Amended and Restated Bylaws (as so amended and restated, the “Amended Bylaws”) to, among other things: i. allow the Company to disregard votes for any nominee made by a shareholder that do not comply with the universal proxy rules adopted by the U.S. Securities and Exchange Commission (“SEC”), including the requirement for shareholder proponents to solicit holders of 67% of outstanding shares; ii. clarify and enhance disclosures in connection with shareholder nominations of directors and submissions of proposals regarding other business at shareholder meetings, including by (a) refining disclosures of synthetic equity to utilize SEC-defined terms, (b) adding disclosures about the dates and intent of the shareholder’s investment, and (c) requiring the language of any bylaw amendments and information otherwise in the proxy statement; iii. clarify and enhance procedural mechanics and disclosure requirements in connection with shareholder nominations of directors and submissions of proposals regarding other business at shareholder meetings, including by (a) prohibiting nomination of more candidates than the number of directors up for election at the applicable meeting, (b) requiring that a shareholder be a record holder to request the required questionnaires for a nominee to complete, and (c) requiring the shareholder be present in person at the shareholder meeting; iv. require that any shareholder directly or indirectly soliciting proxies from other shareholders use a proxy card color other than white; v. provide logistics for shareholders to request a record date to determine who can call a special meeting of shareholders and require disclosures from the requesting shareholder similar to those for submitting nominations and proposals at an annual meeting of shareholders; vi. change the voting standard for corporate actions (other than elections) to a majority of votes cast (excluding abstentions and broker non-votes); and vii. make certain other technical amendments to conform to applicable law.

[12] ISRG Yahoo原始日线：2026-09-08完整交易日

发布日期：2026-09-08行情；2026-09-09抓取

证据文件：/mnt/q/private/stock_site/data/batches/20260909/market/ISRG-raw.json

"regularMarketPrice":350.16

[13] Intuitive Q2完整业绩重新抓取

发布日期：2026-07-16

证据文件：/mnt/q/private/stock_site/data/batches/20260911/evidence/010_IntuitiveSurgical/fetch_17.txt

SUNNYVALE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended June 30, 2026. **Q****2**** Highlights** - Worldwide procedures (da Vinci and Ion combined) grew approximately 16% compared with the second quarter of 2025. Da Vinci procedures grew approximately 15%, and Ion procedures grew approximately 36%. - The Company placed 468 da Vinci surgical systems, compared with 395 in the second quarter of 2025. The second quarter 2026 da Vinci surgical system placements included 246 da Vinci 5 systems, compared with 180 in the second quarter of 2025. The Company placed 55 Ion endoluminal systems, compared with 54 in the second quarter of 2025. - The Company grew its da Vinci surgical system installed base to 11,710 systems as of June 30, 2026, an increase of 12% compared with 10,488 as of June 30, 2025. The Company grew its Ion endoluminal system installed base to 1,096 systems as of June 30, 2026, an increase of 21% compared with 905 as of June 30, 2025. - Second quarter 2026 revenue of $2.89 billion increased 19%, compared with $2.44 billion in the second quarter of 2025. - Second quarter 2026 GAAP net income attributable to Intuitive Surgical, Inc. was $818 million, or $2.29 per diluted share, compared with $658 million, or $1.81 per diluted share, in the second quarter of 2025. - Second quarter 2026 non-GAAP* net income attributable to Intuitive Surgical, Inc. was $1.00 billion, or $2.80 per diluted share, compared with $0.80 billion, or $2.19 per diluted share, in the second quarter of 2025. - Second quarter 2026 GAAP and non-GAAP* net income attributable to Intuitive Surgical, Inc. included a benefit of $28 million, net of tax, or $0.08 per diluted share, related to refunds for tariffs paid in prior periods under the International Emergency Economic Powers Act (“IEEPA”). - The Company repurchased 0.9 million shares of its common stock for $0.38 billion in the second quarter of 2026. **Q****2**** Financial Summary** Gross profit, income from operations, net income attributable to Intuitive Surgical, Inc., and net income per diluted share attributable to Intuitive Surgical, Inc. are reported on a GAAP and non-GAAP* basis. The non-GAAP* measures are described below and are reconciled to the corresponding GAAP measures at the end of this release. Second quarter 2026 revenue was $2.89 billion, an increase of 19% compared with $2.44 billion in the second quarter of 2025. The higher second quarter revenue was driven by growth in procedure volume, higher da Vinci system leasing revenue, and an increase in the installed base of da Vinci and Ion systems. Second quarter 2026 instruments and accessories revenue increased by 18% to $1.73 billion, compared with $1.47 billion in the second quarter of 2025. The increase in instruments and accessories revenue was primarily driven by approximately 15% growth in da Vinci procedure volume and approximately 36% growth in Ion procedure volume. Second quarter 2026 systems revenue was $685 million, compared with $575 million in the second quarter of 2025. The higher systems revenue reflected a higher lease installed base, higher da Vinci system average selling prices, and increased da Vinci system placements compared with the second quarter of 2025. The Company placed 468 da Vinci surgical systems, of which 246 were da Vinci 5 systems, in the second quarter of 2026, compared with 395 systems, of which 180 were da Vinci 5 systems, in the second quarter of 2025. The second quarter 2026 da Vinci surgical system placements included 254 systems placed under operating lease arrangements, of which 131 systems were placed under usage-based operating lease arrangements, compared with 193 systems placed under operating lease arrangements, of which 124 systems were placed under usage-based operating lease arrangements in the second quarter of 2025. Second quarter 2026 GAAP income from operations increased to $972 million, compared with $743 million in the second quarter of 2025. Second quarter 2026 GAAP income from operations included share-based compensation expense of $213 million, compared with $200 million in the second quarter of 2025. Second quarter 2026 non-GAAP* income from operations increased to $1.22 billion, compared with $0.95 billion in the second quarter of 2025. Second quarter 2026 GAAP net income attributable to Intuitive Surgical, Inc. was $818 million, or $2.29 per diluted share, compared with $658 million, or $1.81 per diluted share, in the second quarter of 2025. Second quarter 2026 GAAP net income attributable to Intuitive Surgical, Inc. included excess tax benefits of $17 million, or $0.05 per diluted share, compared with $33 million, or $0.09 per diluted share, in the second quarter of 2025. Additionally, second quarter 2026 GAAP net income included a benefit of $28 million, net of tax, or $0.08 per diluted share, related to refunds for tariffs paid in prior periods under IEEPA. Second quarter 2026 non-GAAP* net income attributable to Intuitive Surgical, Inc. was $1.00 billion, or $2.80 per diluted share, compared with $0.80 billion, or $2.19 per diluted share, in the second quarter of 2025. Second quarter 2026 non-GAAP* net income included a benefit of $28 million, net of tax, or $0.08 per diluted share, related to refunds for tariffs paid in prior periods under IEEPA. The Company ended the second quarter of 2026 with $8.63 billion in cash, cash equivalents, and investments, an increase of $0.65 billion during the quarter, primarily driven by cash generated from operations, partially offset by cash used for repurchases of common stock. “We are pleased with company performance this quarter, which reflects the strength of our portfolio – from da Vinci and Ion to our growing digital solutions,” said Dave Rosa, Intuitive CEO. “Our commitment to customers around the world – our north star – remains the same: helping them deliver better patient outcomes, better patient and care team experiences, lower costs, and broader access to minimally invasive care.” **2026**** Financial Outlook** The Company expects the following results for the full year of 2026: - Worldwide da Vinci procedure growth of approximately 13.5% to 15.5% in 2026. The Company expects to be closer to the midpoint of this range. - Non-GAAP* gross profit margin to be within a range of 68.0% to 69.0% of revenue in 2026. This range includes an estimated impact from tariffs of 1.0% of revenue. - Non-GAAP* operating expense growth of 11% to 13% in 2026. The range for expected non-GAAP* gross profit margin reflects the Company’s estimates of the adverse impact from tariffs that are currently in effect as of the time of this press release and assumes such tariffs remain in place through the end of the year. Should additional tariffs beyond our expectations be implemented, the additional impact on the Company’s financial results in 2026, including the change in expected non-GAAP* gross profit margin, could be material. The ultimate effect of tariffs will depend on various factors, including the proportion of components procured and finished goods manufactured outside of the United States and the amount, scope, nature, and timing of the tariffs. The 2026 financial outlook provided above includes forward-looking, non-GAAP financial measures, which management uses in measuring performance. We do not provide a reconciliation of non-GAAP outlook measures to corresponding GAAP measures on a forward-looking basis, because we are unable to predict with reasonable certainty the exact timing and ultimate outcome of certain items, including but not limited to legal proceedings, without unreasonable efforts. These items are uncertain, depend on various factors, and could be material to the Company’s results computed in accordance with GAAP. For additional information regarding the nature of these items, refer to the reconciliations of historical GAAP to non-GAAP measures included elsewhere in this release. Additional supplemental financial and procedure information has been posted to the Investor Relations section of the Intuitive website at *[https://isrg.gcs-web.com/](https://isrg.gcs-web.com/)*. **Webcast and Conference Call Information** Intuitive will hold a teleconference at 1:30 p.m. PDT today to discuss the second quarter 2026 financial results. The call will be webcast live and can be accessed on Intuitive’s website at *[www.intuitive.com](http://www.intuitive.com)*. For those individuals planning to participate on the call, registration can be completed online at *[https://edge.media-server.com/mmc/p/dekvotz4/](https://edge.media-server.com/mmc/p/dekvotz4/)* to receive dial-in details and an individual pin. The webcast replay of the call will be made available on our website at *[www.intuitive.com](http://www.intuitive.com)* within 24 hours after the end of the live teleconference and will be accessible for at least 30 days. **About Intuitive** Intuitive (Nasdaq: ISRG), headquartered in Sunnyvale, California, is a global leader in minimally invasive care and the pioneer of robotic-assisted surgery. Our technologies include the da Vinci surgical systems and the Ion endoluminal system. By uniting advanced systems, progressive learning, and value-enhancing services, we help physicians and their teams optimize care delivery to support the best outcomes possible. At Intuitive, we envision a future of care that is less invasive and profoundly better, where diseases are identified early and treated quickly, so patients can get back to what matters most. Product and brand names/logos are trademarks or registered trademarks of Intuitive or their respective owner. See *[www.intuitive.com/trademarks](http://www.intuitive.com/trademarks)*. For more information, please visit the Company’s website at *[www.intuitive.com](http://www.intuitive.com)*. **Forward-Looking Statements** This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Forward-looking statements relate to expectations concerning matters that are not historical facts. Statements using words such as “estimates,” “projects,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “may,” “will,” “could,” “should,” “commit,” “would,” “seek,” “potential,” “targeted,” and similar words and expressions are intended to identify forward-looking statements. These forward-looking statements are necessarily estimates reflecting the judgment of the Company’s management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the forward-looking statements. These forward-looking statements include, but are not limited to the following: statements related to future results of operations, including expected procedure growth in 2026, expected non-GAAP gross profit margins in 2026, and expected non-GAAP operating expense growth in 2026; future financial position; the goals the Company shares with its customers, including improving patient outcomes; the estimated impact from tariffs, including the potential for material adverse impact on the Company’s financial results if additional tariffs beyond the Company’s current expectations are implemented; expectations regarding the continuation of share-based compensation expense as a significant recurring expense; the Company’s strategic vision for the future of minimally invasive care; and the Company’s inability to predict with reasonable certainty the exact timing and ultimate outcome of certain items, including legal proceedings. These forward-looking statements should be considered in light of various important factors, including, but not limited to, the following: the overall macroeconomic environment, which may impact customer spending and the Company’s costs, including tariffs, the levels of inflation, and interest rates; the conflict in Ukraine; conflicts in the Middle East, including Israel and Iran; disruption to the Company’s supply chain, including increased difficulties in obtaining a sufficient supply of materials; curtailed or delayed capital spending by hospitals; the impact of global and regional economic and credit market conditions on healthcare spending; delays in obtaining new product approvals, clearances, or certifications from the United States (“U.S.”) Food and Drug Administration (“FDA”), comparable regulatory authorities, or notified bodies; the risk of the Company’s inability to comply with complex FDA and other regulations, which may result in significant enforcement actions; regulatory approvals, clearances, certifications, and restrictions or any dispute that may occur with any regulatory body; healthcare reform legislation in the U.S. and its impact on hospital spending, reimbursement, and fees levied on certain medical device revenues; changes in hospital admissions and actions by payers to limit or manage surgical procedures; the timing and success of product development and customer acceptance of developed products; the results of any collaborations, in-licensing arrangements, joint ventures, strategic alliances, or partnerships, including the joint venture with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; the Company’s completion of and ability to successfully integrate acquisitions, including the recently completed acquisition of the da Vinci and Ion distribution businesses in Italy, Spain, and Portugal and the transition from a distributor to a direct sales model in those markets; intellectual property positions and litigation; competition from companies offering alternative surgical approaches or robotic-assisted surgical systems, including domestic competitors in certain geographic markets such as China; risks associated with the Company’s operations and any expansion outside of the U.S.; unanticipated manufacturing disruptions or the inability to meet demand for products; the Company’s reliance on sole- and single-sourced suppliers; the results of legal proceedings to which the Company is or may become a party; adverse publicity regarding the Company and the safety of the Company’s products and adequacy of training; the impact of changes to tax legislation, guidance, and int

[14] Intuitive Q2完整SEC 10-Q重新抓取

发布日期：2026-07-21

证据文件：/mnt/q/private/stock_site/data/batches/20260911/evidence/010_IntuitiveSurgical/direct_19.txt

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) Three Months Ended June 30, Six Months Ended June 30, in millions (except per share amounts) 2026 2025 2026 2025 Revenue: Product $ 2,419.9 $ 2,048.8 $ 4,757.0 $ 3,939.2 Service 472.4 391.2 906.1 754.2 Total revenue 2,892.3 2,440.0 5,663.1 4,693.4 Cost of revenue: Product 777.0 686.2 1,557.0 1,356.9 Service 154.9 135.9 315.2 260.9 Total cost of revenue 931.9 822.1 1,872.2 1,617.8 Gross profit 1,960.4 1,617.9 3,790.9 3,075.6 Operating expenses: Selling, general, and administrative 617.9 561.2 1,231.2 1,124.6 Research and development 370.6 313.3 732.5 629.5 Total operating expenses 988.5 874.5 1,963.7 1,754.1 Income from operations 971.9 743.4 1,827.2 1,321.5 Interest and other income, net 82.7 88.7 167.8 179.1 Income before taxes 1,054.6 832.1 1,995.0 1,500.6 Income tax expense 231.4 167.9 345.8 132.7 Net income 823.2 664.2 1,649.2 1,367.9 Less: net income attributable to noncontrolling interest in joint venture 5.1 5.8 9.6 11.1 Net income attributable to Intuitive Surgical, Inc. $ 818.1 $ 658.4 $ 1,639.6 $ 1,356.8 Net income per share attributable to Intuitive Surgical, Inc.: Basic $ 2.31 $ 1.84 $ 4.63 $ 3.79 Diluted $ 2.29 $ 1.81 $ 4.57 $ 3.72 Shares used in computing net income per share attributable to Intuitive Surgical, Inc.: Basic 354.1 358.5 354.5 358.0 Diluted 357.3 364.1 358.5 364.4 Other comprehensive income (loss), net of tax: Unrealized gains (losses) on hedge instruments $ 3.1 $ ( 15.3 ) $ 13.0 $ ( 25.7 ) Unrealized gains (losses) on available-for-sale securities ( 18.7 ) 7.4 ( 42.3 ) 36.5 Foreign currency translation gains (losses) 6.2 38.1 ( 5.3 ) 43.6 Employee benefit plan adjustments 0.2 0.2 ( 0.9 ) 0.3 Other comprehensive income (loss) ( 9.2 ) 30.4 ( 35.5 ) 54.7 Total comprehensive income 814.0 694.6 1,613.7 1,422.6 Less: comprehensive income attributable to noncontrolling interest 6.6 6.1 11.6 11.5 Total comprehensive income attributable to Intuitive Surgical, Inc. $ 807.4 $ 688.5 $ 1,602.1 $ 1,411.1 The accompanying notes are an integral part of these Condensed Consolidated Financial Statements (Unaudited). 4 INTUITIVE SURGICAL, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) Six Months Ended June 30, in millions 2026 2025 Operating activities: Net income $ 1,649.2 $ 1,367.9 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and loss on disposal of property, plant, and equipment 371.2 289.6 Amortization of intangible and other assets 59.9 24.4 Accretion of discounts, amortization of premiums, and (gains) losses on investments, net ( 19.0 ) ( 27.4 ) Gain on sale of business and assets ( 7.9 ) — Deferred income taxes 370.3 ( 29.4 ) Share-based compensation expense 419.4 381.4 Changes in operating assets and liabilities, net of effects of acquisitions: Accounts receivable ( 49.8 ) ( 44.1 ) Inventory ( 514.6 ) ( 494.2 ) Prepaids and other assets ( 179.0 ) ( 141.8 ) Accounts payable 21.4 72.4 Accrued compensation and employee benefits ( 229.7 ) ( 114.9 ) Deferred revenue 44.7 48.8 Other liabilities 36.8 ( 35.7 ) Net cash provided by operating activities 1,972.9 1,297.0 Investing activities: Purchase of investments ( 1,349.1 ) ( 691.8 ) Proceeds from sales of investments 0.1 249.1 Proceeds from maturities of investments 1,106.0 1,190.0 Proceeds from sale of assets 46.0 — Purchase of property, plant, and equipment ( 215.9 ) ( 271.9 ) Acquisition of business, net of cash, and intellectual property and other investing activities ( 528.2 ) ( 1.2 ) Net cash provided by (used in) investing activities ( 941.1 ) 474.2 Financing activities: Proceeds from issuance of common stock relating to employee stock plans 187.4 183.7 Taxes paid related to net share settlement of equity awards ( 365.4 ) ( 386.3 ) Repurchase of common stock ( 1,443.5 ) ( 181.0 ) Other financing activities ( 20.1 ) — Net cash used in financing activities ( 1,641.6 ) ( 383.6 ) Effect of exchange rate changes on cash, cash equivalents, and restricted cash 8.1 ( 3.5 ) Net increase (decrease) in cash, cash equivalents, and restricted cash ( 601.7 ) 1,384.1 Cash, cash equivalents, and restricted cash, beginning of period 3,407.4 2,062.4 Cash, cash equivalents, and restricted cash, end of period $ 2,805.7 $ 3,446.5 Supplemental and non-cash disclosures: Equipment transfers, including operating lease assets, from inventory to property, plant, and equipment $ 419.3 $ 357.2 Acquisition of property, plant, and equipment in accounts payable and accrued liabilities 68.8 74.8 Unsettled common stock repurchases in accrued liabilities 63.5 — The accompanying notes are an integral part of these Condensed Consolidated Financial Statements (Unaudited). 5 INTUITIVE SURGICAL, INC. NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED) In this report, “Intuitive,” the “Company,” “we,” “us,” and “our” refer to Intuitive Surgical, Inc. and its wholly and majority-owned subsidiaries. NOTE 1. DESCRIPTION OF THE BUSINESS Intuitive develops, manufactures, and markets da Vinci ® surgical systems and the Ion ® endoluminal system. The Company’s products and related services enable physicians and healthcare providers to improve the quality of and access to minimally invasive care. The da Vinci surgical system is designed to enable surgeons to perform a wide range of surgical procedures within our targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the first cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Both systems use software, instruments, and accessories. NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation The unaudited condensed consolidated financial statements (“Financial Statements”) and accompanying notes have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. In the opinion of management, the accompanying Financial Statements of Intuitive Surgical, Inc. and its wholly and majority-owned subsidiaries have been prepared on a consistent basis with the audited consolidated financial statements for the fiscal year ended December 31, 2025, and include all adjustments, consisting of normal, recurring adjustments, necessary to fairly state the information set forth herein. All intercompany transactions and account balances have been eliminated in consolidation. Certain information and footnote disclosures typically included in the annual consolidated financial statements have been condensed or omitted. Accordingly, these Financial Statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the SEC on February 3, 2026. The results of operations for the first six months of 2026 are not necessarily indicative of the results to be expected for the entire fiscal year or any future periods. The Financial Statements include the results and balances of the Company’s majority-owned joint ventures, Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd. and Intuitive Surgical-Fosun (HongKong) Co., Ltd. (collectively, the “Joint Venture”), with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma”). The Company holds a controlling financial interest in the Joint Venture, and the noncontrolling interest is reflected as a separate component of the condensed consolidated stockholders’ equity. The noncontrolling interest’s share of the earnings in the Joint Venture is presented separately in the Condensed Consolidated Statements of Comprehensive Income. Risks and Uncertainties The Company’s future results of operations and liquidity could be materially adversely affected by uncertainties surrounding macroeconomic and geopolitical factors in both the U.S. and globally. These uncertainties include any introduction or modification of tariffs or trade barriers, inflationary pressures, elevated interest rates, disruptions in commodity markets stemming from conflicts, such as those between Russia and Ukraine and conflicts in the Middle East, including those with Iran, and supply chain challenges, including constraints on supplier capacity and availability of critical materials and components. Recent tariff changes imposed by the U.S. and other countries have created increased risks and uncertainties surrounding the Company’s future results of operations. The U.S. import tariffs, along with any reciprocal measures by other countries, may increase the Company’s cost of raw materials and finished goods imported from outside of the U.S. Additionally, the Company anticipates that some of its suppliers will incur incremental tariff-related costs, which may be passed on to the Company. The ultimate impact of changes to tariffs or trade barriers will depend on various factors, including the timing, amount, scope, and nature of any tariffs or trade barriers that are implemented. Recently Adopted Accounting Pronouncements In July 2025, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2025-05, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets (“ASU 2025-05”) , which provides a practical expedient and an accounting policy election related to the estimation of expected credit losses for current accounts receivable and current contract assets. The Company adopted ASU 2025-05 effective January 1, 2026, on a prospective basis. In connection with this adoption, the Company elected to apply the practical expedient 6 permitted by the standard, which assumes that current conditions as of the balance sheet date do not change for the remaining life of the assets. The adoption of ASU 2025-05 did not have a material impact on the Company’s condensed consolidated financial statements and related disclosures. Recently Issued Accounting Pronouncements In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. The new disclosure requirements are effective for the Company’s annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently in the

[15] Yahoo ISRG调整后盈利一致预期完整网页

发布日期：2026-09-11抓取

证据文件：/mnt/q/private/stock_site/data/batches/20260911/evidence/010_IntuitiveSurgical/direct_24.txt

Earnings Estimate gaap GAAP nongaap Normalized Currency in USD Current Qtr. (Sep 2026) Next Qtr. (Dec 2026) Current Year (2026) Next Year (2027) No. of Analysts 24 24 27 28 Avg. Estimate 2.64 2.84 10.78 12.07 Low Estimate 2.53 2.72 10.38 11.28 High Estimate 2.76 3.02 11.08 12.72 Year Ago EPS 2.4 2.53 8.93 10.78 Earnings History gaap GAAP nongaap Normalized Currency in USD 9/30/2025 12/31/2025 3/31/2026 6/30/2026 EPS Est. 1.99 2.27 2.11 2.5 EPS Actual 2.4 2.53 2.5 2.8 Difference 0.41 0.26 0.39 0.3 Surprise % 20.70% 11.57% 18.67% 11.86% EPS Trend gaap GAAP nongaap Normalized Currency in USD Current Qtr. (Sep 2026) Next Qtr. (Dec 2026) Current Year (2026) Next Year (2027) Current Estimate 2.64 2.84 10.78 12.07 7 Days Ago 2.64 2.84 10.79 12.07 30 Days Ago 2.64 2.84 10.79 12.07 60 Days Ago 2.59 2.83 10.42 11.79 90 Days Ago 2.59 2.83 10.42 11.79 EPS Revisions gaap GAAP nongaap Normalized Currency in USD Current Qtr. (Sep 2026) Next Qtr. (Dec 2026) Current Year (2026) Next Year (2027) Up Last 7 Days 2 1 1 4 Up Last 30 Days 21 12 1 24 Down Last 7 Days -- 1 -- -- Down Last 30 Days 2 9 -- 1 Growth Estimates Symbol Current Qtr. Next Qtr. Current Year Next Year ISRG 9.96% 12.43% 20.71% 11.99% S&P 500 49.86% 23.93% 31.75% 15.38% Related Tickers ALGN Align Technology, Inc. 150.72 -1.44% BDX Becton, Dickinson and Company 176.42 -1.88% RMD ResMed Inc. 219.58 -0.17% MDLN Medline Inc. 32.39 -4.88% BAX Baxter International Inc. 24.18 -0.86% WST West Pharmaceutical Services, Inc. 344.25 +2.17% WRBY Warby Parker Inc. 24.30 -1.10% COO The Cooper Companies, Inc. 54.17 -14.67% SOLV Solventum Corporation 87.65 -2.64% HOLX Copyright © 2026 Yahoo. All rights reserved. Trending Topics Dow Jones S&P 500 DAX Index Nvidia Tesla DJT Tariffs Explore Further Mortgages Credit Cards Sectors Crypto Heatmap Financial News About Data Disclaimer Help Feedback Sitemap Licensing What's New About Our Ads Terms and Privacy Policy Privacy Dashboard More Info Trending tickers ORCL Oracle Corporation 152.94 -8.69 (-5.38%) ADBE Adobe Inc. 248.83 -6.03 (-2.37%) TNON Tenon Medical, Inc. 5.30 +2.86 (+117.21%) RH RH 134.02 -5.35 (-3.84%) DBGI Digital Brands Group, Inc. 6.79 +3.04 (+81.07%) ADVERTISEMENT Portfolio Portfolio Sign in to access your portfolio Sign in Recently viewed Top gainers SWKS Skyworks Solutions, Inc. 84.03 +7.49 (+9.79%) QRVO Qorvo, Inc. 112.36 +7.12 (+6.77%) VEON VEON Ltd. 69.16 +4.16 (+6

[16] Intuitive SEC submissions快照

发布日期：2026-09-11抓取

证据文件：/mnt/q/private/stock_site/data/batches/20260911/evidence/010_IntuitiveSurgical/submissions.json

{"cik":"0001035267","entityType":"operating","sic":"3842","sicDescription":"Orthopedic, Prosthetic & Surgical Appliances & Supplies","ownerOrg":"08 Industrial Applications and Services","insiderTransactionForOwnerExists":0,"insiderTransactionForIssuerExists":1,"name":"INTUITIVE SURGICAL INC","tickers":["ISRG"],"exchanges":["Nasdaq"],"ein":"770416458","lei":null,"description":"","website":"","investorWebsite":"","category":"Large accelerated filer","fiscalYearEnd":"1231","stateOfIncorporation":"DE","stateOfIncorporationDescription":"DE","addresses":{"mailing":{"street1":"1020 KIFER ROAD","street2":null,"city":"SUNNYVALE","stateOrCountry":"CA","zipCode":"94086","stateOrCountryDescription":"CA","isForeignLocation":0,"foreignStateTerritory":null,"country":null,"countryCode":null},"business":{"street1":"1020 KIFER ROAD","street2":null,"city":"SUNNYVALE","stateOrCountry":"CA","zipCode":"94086","stateOrCountryDescription":"CA","isForeignLocation":null,"foreignStateTerritory":null,"country":null,"countryCode":null}},"phone":"4085232100","flags":"","formerNames":[],"filings":{"recent":{"accessionNumber":["0002010300-26-000031","0001950047-26-009210","0002010300-26-000029","0002010300-26-000027","0001280628-26-000014","0001781750-26-000006","0001950047-26-007955","0001561733-26-000014","0001950047-26-007884","0001950047-26-007879","0002010300-26-000025","0002010300-26-000023","0001035267-26-000063","0001035267-26-000060","0001035267-26-000058","0001035267-26-000047","0001519593-26-0000

[17] Intuitive Brosius最新Form4

发布日期：2026-09-09

证据文件：/mnt/q/private/stock_site/data/batches/20260911/evidence/010_IntuitiveSurgical/form4_000201030026000031.txt

Common Stock 09/08/2026 S (1) 46 D $ 361.23 835 D Common Stock 09/09/2026 S (1) 23 D $ 350.2 812 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Explanation of Responses: 1. The transaction took place in accordance with a Trading Plan that complies with SEC Rule 10b5-1 and expires on February 14, 2027. By: Stephanie Lim-Ignacio For: Brosius, Mark 09/09/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 4: SEC 1474 (03-26)

[18] Medtronic与Cornerstone Robotics官方合作公告

发布日期：2026-09-01

证据文件：/mnt/q/private/stock_site/data/batches/20260911/evidence/010_IntuitiveSurgical/competitor.txt

Partnership expands Medtronic's robotic-assisted surgery portfolio to expand access globally and gives surgeons and health systems more choice and flexibility $700 million investment includes... * _Partnership expands Medtronic's robotic-assisted surgery portfolio to expand access globally and gives surgeons and health systems more choice and flexibility_ * _$700 million investment includes rights to distribute Cornerstone Robotics' Sentire™ surgical system in select markets outside the U.S._ * _Sentire will be a strong complement to Medtronic's Hugo™ robotic-assisted surgery (RAS) system, creating a unique portfolio of robotic solutions_ GALWAY, Ireland , Sept. 1, 2026 / [PRNewswire](http://www.prnewswire.com/) / -- Medtronic, a global leader in healthcare technology, today announced a strategic partnership with Cornerstone Robotics, an innovative surgical robotics company committed to advancing minimally invasive surgery and improving access to the latest surgical care worldwide. The approximately $700 million investment includes rights to distribute Cornerstone Robotics' Sentire™ surgical system in select markets outside the U.S. where the system is market approved. Medtronic will distribute Sentire alongside its Hugo™ robotic-assisted surgery (RAS) system. Together with Medtronic's connected surgical ecosystem, the two complementary platforms will expand access to robotic-assisted surgery and offer surgeons and health systems more choice and flexible solutions designed to meet their diverse needs and reach more patients globally. With global adoption of robotic-assisted surgery still in the single digits, the opportunity to expand access to advanced surgical care for patients, physicians and health systems around the world is significant. Expanded choice and access are critical drivers of the future of robotic assisted surgery. Through this partnership, Medtronic and Cornerstone Robotics are building a multi-port portfolio anchored by the Hugo RAS system and expanded by Sentire, giving customers meaningful flexibility across clinical settings, procedural needs, and economic models. "Our strategy is focused on driving the next generation of minimally invasive surgery, one of our biggest growth opportunities," said Matt Anderson, senior vice president and president, Surgical, Medtronic. ... With Sentire complementing the Hugo RAS system, Medtronic will be the only company offering this two-platform portfolio combined with our surgical ecosystem—giving customers more access, more choice, and flexible ... ** The partnership builds on the momentum of Medtronic's Hugo RAS system, which is now being used in more than 35 countries across six continents, including the United States, where it received FDA clearance ... Procedure growth for the Hugo RAS system is currently more than two times the growth rate of the robotic surgery market, and total procedures are expected to exceed 50,000 globally by the end of Medtronic's ... Medtronic will continue to innovate the capabilities of the Hugo RAS system, including ongoing software upgrades, real-time artificial intelligence across its digital ecosystem, integrated stapling, expanded instrumentation, and clinical indications. The modular, multi-quadrant platform is designed for a broad range of soft-tissue surgical procedures and combines wristed instruments, 3D visualization, and Touch Surgery™ ecosystem with dedicated support for robotics program optimization, service, and training. **Expanding Access Through Sentire Surgical System ** The Sentire system's architecture and immersive console with dual-console capability offer a familiar configuration suited to varying surgeon preferences and clinical needs. Developed entirely in-house by Cornerstone Robotics, Sentire has completed multi-specialty clinical trials and received CE Mark in May 2026 for use in minimally invasive general, gynecologic, thoracic, and urologic surgical procedures in addition to its market approval in China and Singapore. "Since the founding of Cornerstone Robotics, we have been steadfast in our commitment to innovation, excellence and clinical value," said Samuel Au, founder and CEO, Cornerstone Rob

[19] ISRG 2026-09-10原始日线

发布日期：2026-09-10行情；2026-09-11抓取

证据文件：/mnt/q/private/stock_site/data/batches/20260911/market/ISRG-raw.json

"regularMarketPrice":360.46

[20] Wells Fargo会议官方搜索元数据（未取得页面正文）

发布日期：2026-09-09会议；2026-09-11检索

证据文件：/mnt/q/private/stock_site/data/batches/20260911/evidence/010_IntuitiveSurgical/wells_search_metadata.txt

Skip to main navigation INTUITIVE at Wells Fargo Healthcare Conference 09/09/26 - 8:45 AM EDT Add to Outlook [Add to Google Calendar](https://www.google.com/calendar/render?action=TEMPLATE&text= Intuitive Surgical - INTUITIVE at Wells Fargo Healthcare Conference&dates=20260909T124500Z/20260909T124500Z&details=Event Details: https://isrg.intuitive.com/events/event-details/intuitive-wells-fargo-healthcare-conference-1%0A%0AWebcast: https://event.summitcast.com/view/aMepMFxWv3z5SRZ9meKJzp/hHXsG2ahfFssNu5YvyxvXV&location=Encore Boston Harbor&trp=false&sprop=&sprop=name:) Listen to Webcast * Print Page * RSS Feeds * Share Page * Financial Tear Sheet 1. Home 2. Investors 3. INTUITIVE at Wells Fargo Healthcare Conference Copyright © Intuitive Surgical. All Rights Reserved. Product names are trademarks or registered trademarks of Intuitive Surgical or their respective owners. See www.intuitive.com/trademarks . We value your privacy